News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pharming Group Gets U.S. Okay for Prodarsan Trial
August 14, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Biotechnology company Pharming Group on Friday said the U.S. Food and Drug Administration accepted its investigational new drug application for Prodarsan, permitting a clinical trial to proceed.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Policy
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
October 23, 2026
·
2 min read
·
Nick Paul Taylor
Immuno-oncology
ESMO 2026: Marengo’s bispecific antibody shrinks 8 tumor types in Phase 2
October 23, 2026
·
3 min read
·
Michael Gibney
FDA
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
October 23, 2026
·
3 min read
·
Tristan Manalac
Cancer
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
October 22, 2026
·
5 min read
·
Annalee Armstrong